David Happel
CIK 1623567 · President & CEO · last filed 2026-07-22
David Happel is a President & CEO who has filed 17 SEC Form 4 insider transactions across 3 companies since 2014. The most recent filing shows the insider sold $497.1K of SGMT on Jul 22, 2026. Across all open-market trades the lifetime net is −$1.1M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $5.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$5.39M
3
17
-$1.09M
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| SGMT | President & CEO | 741,570 | $7.27 | $5.39M | -$1.09M | 11 | 2026-07-22 |
| Horizon Therapeutics Public Ltd Co (HZNP) Delisted | EVP, Commercial Dev & Strategy | 9,239 | $116.30 | $1.07M | $0 | 1 | 2017-10-26 |
| Raptor Pharmaceutical Corp (RPTP) Delisted | Chief Commercial Officer | 0 | — | — | $0 | 5 | 2016-10-26 |
Recent Filings
17 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-07-22 | SGMT | Sell (S) | −64,051 | -$497.1K | EDGAR |
| 2026-06-01 | SGMT | Grant (A) | — | $0 | EDGAR |
| 2026-02-20 | SGMT | Grant (A) | +128,000 | $0 | EDGAR |
| 2026-02-12 | SGMT | Sell (S) | −12,101 | -$64.9K | EDGAR |
| 2025-07-23 | SGMT | Sell (S) | −65,478 | -$598.1K | EDGAR |
| 2025-02-07 | SGMT | Grant (A) | +116,000 | $0 | EDGAR |
| 2024-03-28 | SGMT | Buy (P) | +12,100 | $63.7K | EDGAR |
| 2023-12-08 | SGMT | Buy (P) | +1,600 | $6.6K | EDGAR |
| 2023-11-21 | SGMT | Grant (A) | +624,910 | $0 | EDGAR |
| 2023-11-20 | SGMT | Buy (P) | +590 | $1.4K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.